The Effect of Slow Release Lanreotide in Korean Acromegalic Ratients.
- Author:
Sang Hwa KIM
1
;
In Myung YANG
;
Kwang Sik SEO
;
Eul Soon IM
;
Seung Joon OH
;
Deog Yoon KIM
;
Jeong Taek WOO
;
Sung Woon KIM
;
Jin Woo KIM
;
Young Seol KIM
;
Sun Woo KIM
;
Young Kil CHOI
Author Information
1. Division of Endocrinology, Department of Internal Medicine, Endocrine Research Institute Kyunghee University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Slow release lanreotide;
Somatostatin analogue;
Acromegaly
- MeSH:
Acromegaly;
Arthralgia;
Diarrhea;
Fatigue;
Fingers;
Growth Hormone-Secreting Pituitary Adenoma;
Humans;
Injections, Subcutaneous;
Insulin-Like Growth Factor Binding Protein 3;
Insulin-Like Growth Factor I;
Octreotide;
Oncogenes;
Paresthesia;
Plasma;
Polymerase Chain Reaction;
Somatostatin
- From:Journal of Korean Society of Endocrinology
1999;14(3):458-471
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Previous studies have shown that somatostatin analogues such as octreotide are effective in suppressing GH and IGF-I levels in acromegaly. The recent availability of slow release lanreotide could avoid the inconveniences associated with either repeated subcutaneous injections or continuous infusions. We investigated the effects of the SR-lanreotide on clinical, biochemical and safety responses in five patients with acromegaly. And we investigated whether the response of the GH level to acute adrninistration of octreotide predicts the response after 12 weeks of treatment with the SR-lanreotide and whether the identification of gsp oncogene could be used as a therapeutic and prognostic clue in treatment with the SR-lanreotide. METHODS: We studied the effects of SR-lanreotide 30 mg administered intramuscularly biweekly for 12 weeks in five Korean acromegalic patients. Subjective improvements in the clinical symptoms of acromegaly and adverse reactions were recorded. During SR-lanreotide treatment, serum GH, IGF-I and IGFBP-3 concentrations were evaluated just before the next injection of the SR-lanreotide. Before the start of SR-lanreotide therapy the sensitivity of GH secretion to the octreotide was tested by measuring the effect of the acute response to 0.1 mg intravenously on plasma GH levels followed until 6 hours after administration of octreotide. Direct polymerase chain reaction sequencing of the gsp oncogene were performed. We compared the responses to SR-lanreotide in patients harboring gsp-positive and gsp-negative somatotroph adenomas. RESULTS: The treatment with SR-lanreotide for 12 weeks could suppress the GH level by more than 50% in four of five patients and normalize the IGF-I in two patients. No correlation was found between the GH level and IGF-I level at the end of the study. The IGFBP-3 level correlated with the IGF-I level in three of five patients. Although the initial GH response to octreotide tended to correlate with the IGF-I response after SR-lanreotide treatment, the results were statistically insignificant. The patients with gsp-positive tumor tended to show a better response to SR-lanreotide. During treatment, there was a reduction in the percentage of patients complaining of joint pain, fatigue, digital paresthesia, and hyperhydrosis. Changes in soft tissue swelling were documented by decreases in finger circumference. The common adverse events were abdominal discomfort, loose stool, and diarrhea. These events were decreased progressively. No patients discontinued the treatment of SR-lanreotide due to adverse events. CONCLUSION: This study showed that SR-lanreotide is effective in controlling acromegalic symptoms as well as GH and IGF-I hypersecretion. This treatment was well tolerated and more convenient for the patients. Further studies are required for clinical outcome of long-term SR-lanreotide treatment and cost-effective analysis.
